Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00808067 · ClinicalTrials.gov registry record · Phase 3
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,897
- Enrollment target
NCT00808067 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 5,897 participants.
The verdict
NCT00808067, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,897 participants
- Enrollment target
Study Summary
The purposes of this study are: 1. To evaluate the long-term safety of dabigatran etexilate 2. To assess the effect of a knowledge translation intervention on patient outcomes
Interventions
- DRUG dabigatran dose 1
- DRUG dabigatran dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,897 participants |
| Start Date | 2008-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00808067
The ClinicalTrials.gov registry entry for NCT00808067 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 5,897 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dabigatran dose 1 is the first listed.
NCT00808067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00808067 about?
NCT00808067 is a clinical study titled "RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial". The purposes of this study are: 1. To evaluate the long-term safety of dabigatran etexilate 2. To assess the effect of a knowledge translation intervention on patient outcomes
What is the current status of trial NCT00808067?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,897 participants. The study started on 2008-11. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00808067?
The interventions under investigation include: dabigatran dose 1 (DRUG), dabigatran dose 2 (DRUG).
Who is sponsoring clinical trial NCT00808067?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.